CCT251236 - CAS:1693731-40-6

您当前的位置：

CCT251236

目录号 : KM5318 CAS No. : 1693731-40-6 纯度 : 98%

Data Sheet 产品使用指南

CCT251236 是通过热休克转录因子 1 (hsf1) 表型筛选得到的有口服活性的吡啶配体，抑制 HSF1 介导的 HSP72 诱导的 IC₅₀ 值为 19 nM。

规格	价格	是否有货
1mg		In-stock
5mg		In-stock
10mg		In-stock
50mg		In-stock
100mg		In-stock
200mg	询价	In-stock
500mg	询价	In-stock

查看所有商品（2）

加入购物车大包装询价

Other Forms of Rapamycin:

Ginkgolide B In-stock
Isoginkgetin In-stock
Ginkgolic acid C17:1 In-stock
Ginkgolic Acid In-stock
Propargyl-PEG4-amine In-stock

KKL Med 的所有产品和服务仅用于科学研究，不能被用于人体，兽医，我们也不向个人提供产品和服务。

生物活性

CCT251236 is an orally available pirin ligand from a heat shock transcription factor 1 (hsf1) phenotypic screen with an IC₅₀ of 19 nM for inhibition of HSF1-mediated HSP72 induction.

体外研究

CCT251236 (0-100 nM; 24hours) displays a desired balance of in vitro properties, while maintaining excellent cellular activity with a pIC50=7.73 ± 0.07 (IC₅₀=19 nM) for inhibition of HSF1-mediated HSP72 induction. The free GI₅₀ is 1.1 nM in SK-OV-3 cells that calculated from the free fraction in the cell assay.
CCT251236 (0-100 nM; 24 hours) blocks 17-AAG induced he HSF1-mediated heat-shock proteins, HSP72 and HSP27 expression as a concentration manner in SK-OV-3 cells.
CCT251236 (0-100 nM; 24 hours), pre-treated with 250 nM 17-AAG for 6h, blocks the induction of HSPA1A mRNA by 17-AAG in a dosedependent manner.

Western Blot Analysis

Cell Line:	SK-OV-3 cells
Concentration:	0 nM; 10 nM; 100 nM
Incubation Time:	24 hours
Result:	Inhibited HSP72 and HSP27 expression at the dose of 10 nM.

RT-PCR

Cell Line:	SK-OV-3 cells
Concentration:	0 nM; 10 nM; 100 nM and 1000 nM
Incubation Time:	24 hours
Result:	Decreased HSPA1A mRNA level.

体内研究

CCT251236 (oral adminstation; 5 or 20 mg/kg) in nontumor bearing immunocompetent BALB/c mice exhibits free C_av value of 2.0 nM and 1.2 nM, respectively.
CCT251236 (oral adminstation; 20 mg/kg; 33 days) has a clear therapeutic efficacy in mice with a tumor growth inhibition (%TGI) of 70% based on final tumor volumes. After 33 days, the mean tumor weights decreases 64% when compares to control group. In addition, the compound’s basicity and high volume of distribution shows in tumor withtumor concentrations of CCT251236 as high as 940 nM.

Animal Model:	Athymic mice with SK-OV-3 cells
Dosage:	20 mg/kg; 33 days
Administration:	Oral adminstation
Result:	Was efficacious in SK-OV-3 cell induced-tumor mice model.

分子式

C₃₂H₃₂N₄O₅

分子量

552.62

CAS号

1693731-40-6

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : ≥ 150 mg/mL (271.43 mM)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.8096 mL	9.0478 mL	18.0956 mL
5 mM	0.3619 mL	1.8096 mL	3.6191 mL
10 mM	0.1810 mL	0.9048 mL	1.8096 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (4.52 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (4.52 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

科研文献

纯度： 98%

Data Sheet

产品使用指南

摩尔计算器
稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量

浓度

体积

分子量*

重置计算

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2

浓度

体积

浓度

体积

重置计算

Other Forms of Rapamycin:

KKL 顾客使用本产品发表的 3 篇科研文献

The molarity calculator equation

The dilution calculator equation